New real-world data show no significant rise in overall cancer incidence with JAK inhibitors for rheumatoid arthritis patients, though skin cancer monitoring remains important.
An international team developed and validated the first global classification criteria for pediatric chronic nonbacterial osteomyelitis, offering a standardized tool to improve research and diagnosis.